KOICHI TAKAHASHI to Fusion Proteins, bcr-abl
This is a "connection" page, showing publications KOICHI TAKAHASHI has written about Fusion Proteins, bcr-abl.
Connection Strength
0.339
-
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
Score: 0.102
-
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
Score: 0.099
-
t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol. 2015 Nov; 90(11):E211-2.
Score: 0.085
-
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
Score: 0.028
-
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.
Score: 0.024